{"nctId":"NCT02640482","briefTitle":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection","startDateStruct":{"date":"2015-11","type":"ACTUAL"},"conditions":["Chronic Hepatitis C Virus (HCV) Infection"],"count":304,"armGroups":[{"label":"Arm A DB Active Drug","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]},{"label":"Arm B DB Placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo for ABT-493/ABT-530"]},{"label":"Arm B OL Active Drug","type":"EXPERIMENTAL","interventionNames":["Drug: ABT-493/ABT-530"]}],"interventions":[{"name":"ABT-493/ABT-530","otherNames":["ABT-493 also known as glecaprevir","ABT-530 also known as pibrentasvir","MAVYRET"]},{"name":"Placebo for ABT-493/ABT-530","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Screening laboratory result indicating hepatitis C virus (HCV) Genotype-2 (GT2) infection.\n* Chronic HCV infection.\n* Subject must be HCV treatment-naïve (subject had never received a single dose of any approved or investigational regimen) or had failed prior interferon (IFN) or pegylated-interferon (pegIFN) ± ribavirin (RBV) or sofosbuvir (SOF) + RBV ± pegIFN therapy.\n* Subject must be non-cirrhotic.\n\nExclusion Criteria:\n\n* History of severe, life-threatening or other significant sensitivity to any excipient of the study drugs.\n* Female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study.\n* Recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator.\n* Positive test result at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody (HIV Ab).\n* HCV genotype performed during screening indicating coinfection with more than 1 HCV genotype.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN Failures: Noninferiority Analysis","description":"SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification \\[\\<LLOQ\\]) 12 weeks after the last dose of active study drug. The primary efficacy endpoint was the noninferiority of the percentage of participants who achieved SVR12 in Arm A Double Blind (DB) Active Drug excluding prior sofosbuvir (SOF) + ribavirin (RBV) ± pegylatedinterferon (pegIFN) failures compared with the historical control rate for patients treated with the current standard of care (SOF + RBV for 12 weeks).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR12 in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN Failures: Superiority Analysis","description":"SVR12 was defined as plasma HCV RNA level \\<LLOQ 12 weeks after the last dose of study drug. The secondary efficacy endpoint was the superiority of the percentage of participants who achieved SVR12 in Arm A Double Blind (DB) Active Drug excluding prior SOF + RBV ± pegIFN failures compared with the historical control rate for patients treated with the current standard of care (SOF + RBV for 12 weeks). As pre-specified in the study protocol, the primary outcome measure and the secondary outcome measure are not tested independently from each other. Rather, the two measures are ranked in a fixed sequential testing procedure that only if success was demonstrated for the primary outcome (i.e. non-inferiority test of Arm A SVR12 rate to the standard of care) did we test the first secondary outcome (i.e. superiority test of Arm A SVR12 rate to the standard of care).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With On-treatment Virologic Failure in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN Failures","description":"On-treatment virologic failure was defined as confirmed increase of \\> 1 log(subscript)10(subscript) IU/mL above the lowest value of post-baseline HCV RNA during treatment; confirmed HCV RNA ≥ 100 IU/mL after HCV RNA \\< LLOQ during treatment, or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Post-treatment Relapse in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN Failures","description":"Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of DB treatment and 12 weeks after the last dose of active study drug among participants who completed treatment with HCV RNA levels \\< LLOQ at the end of treatment, excluding reinfection.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR12 in Arm A DB Active Drug With Prior SOF + RBV ± pegIFN Failure","description":"SVR12 was defined as HCV RNA level \\<LLOQ 12 weeks after the last dose of active study drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":202},"commonTop":["Headache","Fatigue","Asthenia","Diarrhoea","Nausea"]}}}